Lupin Ltd Announces Licensing Deal for Ranibizumab Biosimilar with Sandoz Group AG

Global Pharma major Lupin Limited has partnered with Sandoz Group AG to market and commercialize its biosimilar Ranibizumab across multiple regions. The agreement covers the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia, where Sandoz will oversee commercialization. Lupin will manage manufacturing and regulatory submissions. Sandoz will have exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights. In Canada, Sandoz will acquire sole rights for commercialization, while Lupin will manage manufacture and regulatory filings.